Mineralys Therapeutics Inc
MLYS
Company Profile
Business description
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Contact
150 North Radnor Chester Road
Suite F200
RadnorPA19087
USAT: +1 888 378-6240
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
51
Stocks News & Analysis
stocks
Earnings winners: BHP, NAB & TLS lead the pack
The winners of this weeks earnings that saw strong investor backing
stocks
Walmart earnings: Growth in digital buoys margin amid consumer trade-down
We think Walmart stock is significantly overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,303.20 | 9.30 | 0.10% |
| CAC 40 | 8,507.97 | 109.19 | 1.30% |
| DAX 40 | 25,260.69 | 217.12 | 0.87% |
| Dow JONES (US) | 49,625.97 | 230.81 | 0.47% |
| FTSE 100 | 10,702.10 | 75.06 | 0.71% |
| HKSE | 26,413.35 | 292.59 | -1.10% |
| NASDAQ | 22,886.07 | 203.34 | 0.90% |
| Nikkei 225 | 56,825.70 | 642.13 | -1.12% |
| NZX 50 Index | 13,308.52 | 135.68 | -1.01% |
| S&P 500 | 6,909.51 | 47.62 | 0.69% |
| S&P/ASX 200 | 9,081.40 | 17.00 | 0.19% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |